OPKO Health (OPK) Stock Price, News & Analysis

Company Overview

OPKO Health, Inc. is a healthcare company focused on diagnostics and pharmaceuticals. Through its BioReference Laboratories business, the company provides clinical laboratory services, including routine testing, specialty diagnostics, genetic testing and oncology-related laboratory services. OPKO also develops diagnostic products, including the 4Kscore test, a blood test designed to help assess the risk of aggressive prostate cancer.

In pharmaceuticals, OPKO develops treatments for kidney disease, endocrine disorders and other conditions. Its products include Rayaldee, an extended-release calcifediol formulation used to treat secondary hyperparathyroidism in adults with chronic kidney disease, and NGENLA, a long-acting human growth hormone product developed with Pfizer for certain children with growth hormone deficiency. OPKO also maintains a pipeline of investigational therapies and biologic products.

OPKO serves patients, healthcare providers and commercial partners in the United States and select international markets through its laboratory, pharmaceutical and biotechnology operations. The company is led by Phillip Frost, who serves as chairman and chief executive officer. OPKO has expanded its business over time through the development and acquisition of diagnostic and pharmaceutical assets, including BioReference Laboratories.

Key Stats

• Today's Range: $1.71 to $1.86
• 50-Day Range: $1.32 to $1.77
• 52-Week Range: $0.98 to $1.86
• Volume: 6.90 million shs
• Average Volume: 6.11 million shs
• Market Capitalization: $1.29 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $3.42
• Consensus Rating: Moderate Buy

OPKO Health Stock Analysis - MarketRank™

OPKO Health scored higher than 64% of companies evaluated by MarketBeat, and ranked 310th out of 886 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

OPKO Health has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 1 strong buy rating, 4 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

OPKO Health has a consensus price target of $3.42, representing about 97.5% upside from its current price of $1.73.

Amount of Analyst Coverage

OPKO Health has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for OPKO Health are expected to decrease in the coming year, from ($0.22) to ($0.28) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of OPKO Health is -9.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of OPKO Health is -9.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

OPKO Health has a P/B Ratio of 1.15. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

8.24% of the float of OPKO Health has been sold short.

Short Interest Ratio / Days to Cover

OPKO Health has a short interest ratio ("days to cover") of 5.26.

Change versus previous month

Short interest in OPKO Health has recently decreased by 4.36%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

OPKO Health does not currently pay a dividend.

Dividend Growth

OPKO Health does not have a long track record of dividend growth.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 0.28

News Sentiment

OPKO Health has a news sentiment score of 0.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 29 news articles for OPKO Health this week, compared to 5 articles on an average week.

Search Interest

Only 2 people have searched for OPK on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

MarketBeat Follows

7 people have added OPKO Health to their MarketBeat watchlist in the last 30 days. This is an increase of 600% compared to the previous 30 days.

Company Ownership

• Score: 2.1 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, OPKO Health insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $24,577.00 in company stock.

Percentage Held by Insiders

44.72% of the stock of OPKO Health is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

64.63% of the stock of OPKO Health is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 11/04/2026
• Today: 11/08/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Providers & Services
• Sub-Industry: Healthcare Services
• Current Symbol: NASDAQ:OPK
• CIK: 944809
• Web: www.opko.com
• Phone: (305) 575-4100
• Fax: 305-575-6015
• Employees: 1,373
• Year Founded: 2007

Price Target and Rating

• Average Price Target for OPKO Health: $3.42
• High Price Target: $4.00
• Low Price Target: $2.25
• Potential Upside/Downside: +97.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.71
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.19)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$225.68 million
• Net Margins: -29.51%
• Pretax Margin: -15.30%
• Return on Equity: -10.90%
• Return on Assets: -6.93%

Debt

• Debt-to-Equity Ratio: 0.41
• Current Ratio: 4.97
• Quick Ratio: 2.93

Sales & Book Value

• Annual Sales: $654.10 million
• Price / Sales: 1.97
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.50 per share
• Price / Book: 1.15

Miscellaneous

• Outstanding Shares: 746,328,000
• Free Float: 412,570,000
• Market Cap: $1.29 billion
• Optionable: Optionable
• Beta: 1.52